Nuvation Bio, Inc.(NUVB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NUVB Nuvation Bio, Inc.

Market Closed 12-12 16:00:00 EST

8.43

+0.16

+1.93%

盘后8.36

-0.07-0.83%

19:58 EST

High8.55	Low8.00	Vol6.07M
Open8.21	D1 Closing8.27	Amplitude6.65%
Mkt Cap2.89B	Tradable Cap1.95B	Total Shares342.83M
T/O51.24M	T/O Rate2.63%	Tradable Shares231.05M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NUVB","market":"US","secType":"STK","nameCN":"Nuvation Bio, Inc.","latestPrice":8.43,"timestamp":1765573200000,"preClose":8.27,"halted":0,"volume":6074688,"hourTrading":{"tag":"盘后","latestPrice":8.36,"preClose":8.43,"latestTime":"19:58 EST","volume":77160,"amount":650445.9031,"timestamp":1765587518175},"delay":0,"floatShares":231046340,"shares":342833433,"eps":-0.640012,"marketStatus":"Market Closed","change":0.16,"latestTime":"12-12 16:00:00 EST","open":8.21,"high":8.55,"low":8,"amount":51244379.204736,"amplitude":0.066505,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.640012,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"exchange":"NYSE","adjPreClose":8.27,"preHourTrading":{"tag":"盘前","latestPrice":8.2611,"preClose":8.27,"latestTime":"09:19 EST","volume":2417,"amount":20053.766821999998,"timestamp":1765549175133},"postHourTrading":{"tag":"盘后","latestPrice":8.36,"preClose":8.43,"latestTime":"19:58 EST","volume":77160,"amount":650445.9031,"timestamp":1765587518175},"volumeRatio":0.9303351538772652,"impliedVol":1.1619,"impliedVolPercentile":0.544},"requestUrl":"/m/hq/s/NUVB/tweets","defaultTab":"tweets","newsList":[{"id":"2590590111","title":"Nuvation Bio Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2590590111","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590590111?lang=en_us&edition=fundamental","pubTime":"2025-12-11 19:32","pubTimestamp":1765452720,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NUVB/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 11, 2025 06:32 ET (11:32 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUVB","BK4007"],"gpt_icon":0},{"id":"2590597498","title":"Nuvation Bio Inc. : H.c. Wainwright Raises Target Price to $18 From $10","url":"https://stock-news.laohu8.com/highlight/detail?id=2590597498","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590597498?lang=en_us&edition=fundamental","pubTime":"2025-12-11 19:09","pubTimestamp":1765451359,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nAZN4RD75K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NUVB"],"gpt_icon":0},{"id":"2589087066","title":"Why Nuvation Bio (NUVB) Is Up 6.5% After Strong Safusidenib Phase 2 Glioma Data And What's Next","url":"https://stock-news.laohu8.com/highlight/detail?id=2589087066","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589087066?lang=en_us&edition=fundamental","pubTime":"2025-12-07 22:17","pubTimestamp":1765117056,"startTime":"0","endTime":"0","summary":"Nuvation Bio recently reported encouraging Phase 2 trial results for safusidenib in IDH1-mutant grade 2 gliomas, achieving its primary endpoint with a 44.4 percent objective response rate and a manageable safety profile.\nThese data, which suggest safusidenib may help delay chemoradiation and preserve quality of life, have drawn increased attention from both management and analysts to Nuvation Bio’s emerging oncology pipeline.\nWe’ll now examine how the promising safusidenib Phase 2 results...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-nuvb/nuvation-bio/news/why-nuvation-bio-nuvb-is-up-65-after-strong-safusidenib-phas","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-nuvb/nuvation-bio/news/why-nuvation-bio-nuvb-is-up-65-after-strong-safusidenib-phas","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NUVB","BK4007"],"gpt_icon":0},{"id":"2589873869","title":"Innovent Announces Inclusion of Seven Innovative Drugs Including Tyvyt New Indication and Sycume in China's National Reimbursement Drug List","url":"https://stock-news.laohu8.com/highlight/detail?id=2589873869","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589873869?lang=en_us&edition=fundamental","pubTime":"2025-12-07 11:40","pubTimestamp":1765078825,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251207:nTUA97Z24L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NUVB","BK1161","LU2488822045.USD","HK0000165453.HKD","BK1589","BK4007","LU2097828557.USD","LU2097828474.EUR","BK1583","LU1969619763.USD","LU2097828631.EUR","LU2097828714.EUR","LU0502904849.HKD","LU2097828805.USD","LU2242644610.SGD","LU0455707207.USD","01801","LU2328871848.SGD"],"gpt_icon":0},{"id":"2588022904","title":"Nuvation Bio Chief Medical Officer Dongfang Liu Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2588022904","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588022904?lang=en_us&edition=fundamental","pubTime":"2025-12-04 06:02","pubTimestamp":1764799370,"startTime":"0","endTime":"0","summary":"Dongfang Liu, Chief Medical Officer of Nuvation Bio Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvation Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 03, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDL1jT0FT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Nuvation Bio Chief Medical Officer Dongfang Liu Reports Sale of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NUVB"],"gpt_icon":0},{"id":"2588502650","title":"BUZZ-U.S. STOCKS ON THE MOVE-Spirit AeroSystems, Boeing, Roblox","url":"https://stock-news.laohu8.com/highlight/detail?id=2588502650","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588502650?lang=en_us&edition=fundamental","pubTime":"2025-12-04 02:53","pubTimestamp":1764788004,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Spirit AeroSystems, Boeing, RobloxEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter:","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nL6N3X90ND:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["THO","BDTX","TRGP","GTLB","SPR","STRK","CXM","CVX","FCX","CASY","LU0689626769.HKD","AU","KMTS","PSTG","CNX","RBLX","CBSH","WEN","BMY","CBU","NEXT","NXT","XOM","APA","DAKT","AEO","FNB","IXHL","DLTR","NUVB","CAPR","ARE","OKTA","MCHP","PHVS","EQT","SCCO","BA","MRBK","EQIX","CHCO"],"gpt_icon":1},{"id":"2588040270","title":"BUZZ-U.S. STOCKS ON THE MOVE-Microsoft, Wyndham Hotels & Resorts, Daktronics","url":"https://stock-news.laohu8.com/highlight/detail?id=2588040270","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588040270?lang=en_us&edition=fundamental","pubTime":"2025-12-03 23:57","pubTimestamp":1764777433,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Microsoft, Wyndham Hotels & Resorts, DaktronicsEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Cal","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nL6N3X90XO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AEO","LU0300736062.USD","SCCO","MRBK","ARE","OKTA","BDTX","CVX","GTLB","DLTR","APA","CHCO","GB00B4LPDJ14.GBP","DAKT","CAPR","STRK","THO","BMY","LU0689472784.USD","NUVB","SG9999018857.SGD","IXHL","LU0314104364.USD","LU1712237335.SGD","NXT","SG9999014880.SGD","LU0266512127.USD","CXM","PHVS","LU2602419157.SGD","AU","WEN","MSFT","FCX","XOM","CBU","EQIX","MCHP","PSTG","TRGP","FNB","CASY","KMTS"],"gpt_icon":1},{"id":"2588049600","title":"BUZZ-Nuvation Bio rises on brain cancer drug data","url":"https://stock-news.laohu8.com/highlight/detail?id=2588049600","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588049600?lang=en_us&edition=fundamental","pubTime":"2025-12-03 21:12","pubTimestamp":1764767535,"startTime":"0","endTime":"0","summary":"BUZZ-Nuvation Bio rises on brain cancer drug data** Shares of drugmaker Nuvation Bio NUVB.N rise 1.5% to $7.58 premarket** Co says experimental drug safusidenib met main goal in mid-stage trial for grade 2 IDH1-mutant glioma, a type of brain cancer** 44% of patients saw tumors shrink or disappear; 88% had no disease progression after two years, co says** Co plans to expand study into larger trial after FDA agreement on design changes - NUVB** NUVB's safusidenib is an oral drug targeting tumors with IDH1 mutation, co says** Up to last close, stock was up ~181% YTD","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nL4N3X9106:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NUVB"],"gpt_icon":0},{"id":"2588104625","title":"Nuvation Bio Reports Positive Phase 2 Results for Safusidenib in IDH1-Mutant Glioma","url":"https://stock-news.laohu8.com/highlight/detail?id=2588104625","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588104625?lang=en_us&edition=fundamental","pubTime":"2025-12-03 21:00","pubTimestamp":1764766853,"startTime":"0","endTime":"0","summary":"Nuvation Bio Inc. has announced the publication of positive results from a Phase 2 study evaluating safusidenib, an oral inhibitor of mutant IDH1, in patients with chemotherapy- and radiotherapy-nave grade 2 IDH1-mutant gliomas. The study, published in the journal Neuro-Oncology on November 8, assessed 27 patients and reported an objective response rate of 44.4%, with 87.9% of patients progression-free at 24 months. Median progression-free survival was not reached at a median follow-up of 28 months. The results support ongoing discussions with the FDA regarding the ongoing G203 study, which is being amended into a pivotal global Phase 3 trial in high-grade gliomas. A trial-in-progress poster on the G203 study was presented at the 30th Annual Meeting of the Society for Neuro-Oncology on November 21. A Good Clinical Practice noncompliance issue related to adverse event collection was identified and subsequently addressed through a re-investigation and re-collection of safety data.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDL2vzZ4n:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUVB","BK4007"],"gpt_icon":0},{"id":"2588046246","title":"Nuvation Bio Announces Publication of Positive Phase 2 Study Results for Safusidenib for the Treatment of Grade 2 Idh1-Mutant Glioma in Neuro-Oncology","url":"https://stock-news.laohu8.com/highlight/detail?id=2588046246","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588046246?lang=en_us&edition=fundamental","pubTime":"2025-12-03 21:00","pubTimestamp":1764766803,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nTUA7FBS2F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NUVB","BK4007"],"gpt_icon":0},{"id":"2588776771","title":"Nuvation Bio Inc. highlights pipeline progress and IBTROZI launch in oncology-focused corporate presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2588776771","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588776771?lang=en_us&edition=fundamental","pubTime":"2025-12-01 23:09","pubTimestamp":1764601748,"startTime":"0","endTime":"0","summary":"Nuvation Bio Inc. has provided an update on its oncology pipeline and commercial activities. The company highlighted the approval of IBTROZI , a next-generation ROS1 inhibitor, for advanced ROS1-positive non-small cell lung cancer  in the United States, Japan, and China. As of September 30, 2025, 204 patients in the U.S. have started treatment with IBTROZI in the third quarter, and confirmed payor coverage extends to 80% of eligible lives. Nuvation Bio also reported progress on its clinical and preclinical programs, including safusidenib, which is entering a pivotal study for high-grade IDH1-mutant glioma, and NUV-868, a BD2-selective BET inhibitor that has completed Phase 1 and 1b studies. The company continues to evaluate additional candidates from its proprietary Drug-Drug Conjugate  platform. Nuvation Bio reported a cash balance of $549 million as of September 30, 2025, with further funding available under an existing loan facility. You can access the full presentation through the ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDL3Ttq3L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NUVB"],"gpt_icon":0},{"id":"2588472450","title":"Nuvation Bio Price Target Maintained With a $10.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2588472450","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588472450?lang=en_us&edition=fundamental","pubTime":"2025-12-01 19:45","pubTimestamp":1764589500,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NUVB/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 01, 2025 06:45 ET (11:45 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NUVB"],"gpt_icon":0},{"id":"2587798198","title":"Truist Financial Sticks to Their Buy Rating for Nuvation Bio (NUVB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2587798198","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587798198?lang=en_us&edition=fundamental","pubTime":"2025-11-30 11:25","pubTimestamp":1764473105,"startTime":"0","endTime":"0","summary":"In a report released on November 28, from Truist Financial maintained a Buy rating on Nuvation Bio. The company’s shares closed last Friday at $8.0...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/truist-financial-sticks-to-their-buy-rating-for-nuvation-bio-nuvb-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/truist-financial-sticks-to-their-buy-rating-for-nuvation-bio-nuvb-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NUVB"],"gpt_icon":0},{"id":"2586260977","title":"Nuvation Bio Executives to Join Fireside Chats at Major Healthcare Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2586260977","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586260977?lang=en_us&edition=fundamental","pubTime":"2025-11-27 05:05","pubTimestamp":1764191122,"startTime":"0","endTime":"0","summary":"Nuvation Bio Inc. will participate in two upcoming investor conferences in Miami, FL. The company's Founder, President, and CEO, David Hung, M.D., and Chief Financial Officer, Philippe Sauvage, will join fireside chats at the 8th Annual Evercore Healthcare Conference on December 2, 2025, at 9:35 a.m. ET, and at the Citi 2025 Global Healthcare Conference on December 3, 2025, at 9:00 a.m. ET. Live webcasts and archived recordings of both events will be available on the Investor Relations section of the Nuvation Bio website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvation Bio Inc. published the original content used to generate this news brief via Business Wire  on November 26, 2025, and is solely responsible for the information c","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nNDL7yBGD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4504","LU0320765646.SGD","LU0098860793.USD","LU1267930227.SGD","LU2462157665.USD","LU2125154935.USD","LU0130102774.USD","LU2456880835.USD","LU1668664300.SGD","LU0477156953.USD","LU0128525689.USD","BK4588","IE00BSNM7G36.USD","NUVB","LU1791807156.HKD","BK4585","LU2417539215.USD","LU2125154778.USD","BK4559","LU1162221912.USD","LU0052756011.USD","LU0170899867.USD","LU0648001328.SGD","LU0162691827.USD","BK4207","LU2236285917.USD","LU2360032135.SGD","BK4534","LU0310800965.SGD","LU0980610538.SGD","LU0130517989.USD","BK4007","LU1366192091.USD","LU0106831901.USD","BK4566","EVR","LU1244550577.SGD","LU1244550221.USD","BK4127","LU1244550494.USD","LU0072461881.USD","LU1201861249.SGD"],"gpt_icon":0},{"id":"2586264511","title":"Nuvation Bio to discontinue development of NUV-1511","url":"https://stock-news.laohu8.com/highlight/detail?id=2586264511","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586264511?lang=en_us&edition=fundamental","pubTime":"2025-11-27 01:40","pubTimestamp":1764178821,"startTime":"0","endTime":"0","summary":"In a regulatory filing, Nuvation Bio (NUVB) announced its decision to discontinue development of NUV-1511, the first compound in its first-of-its-k...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nuvation-bio-to-discontinue-development-of-nuv-1511-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nuvation-bio-to-discontinue-development-of-nuv-1511-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NUV","BK4007","NUVB"],"gpt_icon":0},{"id":"2586517264","title":"Clear Street says thesis intact after Nuvation’s NUV-1511 discontinued","url":"https://stock-news.laohu8.com/highlight/detail?id=2586517264","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586517264?lang=en_us&edition=fundamental","pubTime":"2025-11-27 01:40","pubTimestamp":1764178815,"startTime":"0","endTime":"0","summary":"Clear Street reiterates a Buy rating and $12 price target on shares of Nuvation Bio (NUVB) after the company announced that it has discontinued dev...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/clear-street-says-thesis-intact-after-nuvations-nuv-1511-discontinued-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/clear-street-says-thesis-intact-after-nuvations-nuv-1511-discontinued-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NUVB","BK4007","NUV"],"gpt_icon":0},{"id":"2586257248","title":"Nuvation Bio Inc - Discontinues Development of Nuv-1511 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2586257248","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586257248?lang=en_us&edition=fundamental","pubTime":"2025-11-26 21:35","pubTimestamp":1764164108,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nFWN3X20NM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NUVB","BK4007"],"gpt_icon":0},{"id":"2586257244","title":"Nuvation Bio: Nuv-1511 Well Tolerated, Did Demonstrate Promising Signals in Some Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2586257244","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586257244?lang=en_us&edition=fundamental","pubTime":"2025-11-26 21:35","pubTimestamp":1764164108,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nFWN3X20NM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NUVB"],"gpt_icon":0},{"id":"2586257227","title":"Nuvation Bio Inc: Co Has Made This Decision Due to Lack of Sufficiently Consistent Efficacy Across Cohorts","url":"https://stock-news.laohu8.com/highlight/detail?id=2586257227","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586257227?lang=en_us&edition=fundamental","pubTime":"2025-11-26 21:35","pubTimestamp":1764164108,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nFWN3X20NM:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NUVB"],"gpt_icon":0},{"id":"2586224257","title":"Nuvation Bio: Resources Budgeted for Nuv-1511 to Be Transferred to Other Pipeline Molecules & to Development of DDC Candidates","url":"https://stock-news.laohu8.com/highlight/detail?id=2586224257","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586224257?lang=en_us&edition=fundamental","pubTime":"2025-11-26 21:35","pubTimestamp":1764164108,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nFWN3X20NM:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NUVB","BK4007"],"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.014},{"period":"1month","weight":0.7099},{"period":"3month","weight":1.6847},{"period":"6month","weight":3.8728},{"period":"1year","weight":2.2053},{"period":"ytd","weight":2.1692}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Nuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio's proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung , M.D., who previously founded Medivation, Inc., which brought to patients one of the world's leading prostate cancer medicines. Nuvation Bio has offices in New York and San Francisco .","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.036753},{"month":2,"riseRate":0.2,"avgChangeRate":-0.07924},{"month":3,"riseRate":0.6,"avgChangeRate":0.155399},{"month":4,"riseRate":0.4,"avgChangeRate":0.005292},{"month":5,"riseRate":0.6,"avgChangeRate":0.002702},{"month":6,"riseRate":0.2,"avgChangeRate":-0.090917},{"month":7,"riseRate":0.6,"avgChangeRate":0.065913},{"month":8,"riseRate":0.6,"avgChangeRate":0.013694},{"month":9,"riseRate":0.5,"avgChangeRate":-0.038205},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.016548},{"month":11,"riseRate":0.5,"avgChangeRate":0.163132},{"month":12,"riseRate":0.666667,"avgChangeRate":0.050496}],"exchange":"NYSE","name":"Nuvation Bio, Inc.","nameEN":"Nuvation Bio, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Nuvation Bio, Inc.(NUVB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Nuvation Bio, Inc.(NUVB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Nuvation Bio, Inc.,NUVB,Nuvation Bio, Inc.股票,Nuvation Bio, Inc.股票老虎,Nuvation Bio, Inc.股票老虎国际,Nuvation Bio, Inc.行情,Nuvation Bio, Inc.股票行情,Nuvation Bio, Inc.股价,Nuvation Bio, Inc.股市,Nuvation Bio, Inc.股票价格,Nuvation Bio, Inc.股票交易,Nuvation Bio, Inc.股票购买,Nuvation Bio, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Nuvation Bio, Inc.(NUVB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Nuvation Bio, Inc.(NUVB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}